Home » Stocks » XENE

Xenon Pharmaceuticals Inc. (XENE)

Stock Price: $18.25 USD 0.20 (1.08%)
Updated Jun 21, 2021 11:49 AM EDT - Market open
Market Cap 739.46M
Revenue (ttm) 29.45M
Net Income (ttm) -36.09M
Shares Out 40.97M
EPS (ttm) -1.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $18.25
Previous Close $18.05
Change ($) 0.20
Change (%) 1.08%
Day's Open 18.16
Day's Range 17.78 - 18.56
Day's Volume 81,864
52-Week Range 9.32 - 21.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BURNABY, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annua...

2 weeks ago - GlobeNewsWire

BURNABY, British Columbia, May 31, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management...

2 weeks ago - GlobeNewsWire

Topline Data from XEN1101 Phase 2b “X-TOLE” Clinical Trial Anticipated by End of Third Quarter of 2021

1 month ago - GlobeNewsWire

BURNABY, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive manageme...

2 months ago - GlobeNewsWire

BURNABY, British Columbia, March 29, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the Company will participate in a...

2 months ago - GlobeNewsWire

BURNABY, British Columbia, March 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announce...

3 months ago - GlobeNewsWire

BURNABY, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public...

3 months ago - GlobeNewsWire

BURNABY, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) --  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten...

3 months ago - GlobeNewsWire

U.S. FDA IND acceptance and IRB approval in place for investigator-sponsored trial, expected to be initiated in the second quarter of 2021 U.S. FDA IND acceptance and IRB approval in place for investiga...

3 months ago - GlobeNewsWire

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 15.00% and 47.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Xenon Pharmaceuticals (NASDAQ:XENE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 17.07% over the past year to ($0.34)...

3 months ago - Benzinga

XEN1101 Phase 2b “X-TOLE” Clinical Trial in Adult Focal Epilepsy on Track for Topline Data in  Third Quarter of 2021

3 months ago - GlobeNewsWire

Xenon to Participate in Fireside Discussion at SVB Leerink 10th Annual Global Healthcare Conference Xenon to Participate in Fireside Discussion at SVB Leerink 10th Annual Global Healthcare Conference

3 months ago - GlobeNewsWire

Pre-Clinical Data Support the Potential Benefit of XEN1101 to Treat Depression and Anhedonia

3 months ago - GlobeNewsWire

Early, Promising Data from Physician-Led Phase 2 Open Label Clinical Trial Support XEN007 as a Potential Treatment of Childhood Absence Epilepsy (CAE) Early, Promising Data from Physician-Led Phase 2 Op...

6 months ago - GlobeNewsWire

BURNABY, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief ...

7 months ago - GlobeNewsWire

Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -66.67% and -36.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Shares have risen by 15% since my March recommendation, but EV of around $180 million appears cheap contrasted to multiple opportunities in epilepsy that they are pursuing. I provide a recap of our bull...

7 months ago - Seeking Alpha

BURNABY, British Columbia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its third quarter 2...

7 months ago - GlobeNewsWire

Positive Opinion Received Supporting Orphan Medicinal Product Designation in Europe for XEN496 for the Treatment of KCNQ2-DEE Positive Opinion Received Supporting Orphan Medicinal Product Designation in...

8 months ago - GlobeNewsWire

U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients

8 months ago - GlobeNewsWire

BURNABY, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced today the appointment of Dr. Chris Von S...

10 months ago - GlobeNewsWire

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 100.00% and 102.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020

10 months ago - GlobeNewsWire

BURNABY, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its second quarte...

10 months ago - GlobeNewsWire

BELLEVUE, Wash.--(BUSINESS WIRE)--Xenon arc Unveils Groundbreaking Voice of Customer Study Results Focused on Small-to-Mid Sized Business Customers

10 months ago - Business Wire

LONDON--(BUSINESS WIRE)-- #GlobalXenonFlashLampMarket--The Global Xenon Flash Lamp Market will grow by $ 46.40 mn during 2020-2024

11 months ago - Business Wire

Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 29.03% and -5.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs 

1 year ago - GlobeNewsWire

Xenon Remains Well-Positioned And Well-Funded Despite COVID-19 Related Setbacks

1 year ago - Seeking Alpha

BURNABY, British Columbia, March 31, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update in the context of ...

1 year ago - GlobeNewsWire

BURNABY, British Columbia, March 26, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced equity inducement grants to eight ne...

1 year ago - GlobeNewsWire

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

If you can handle the uncertainty, these small-cap stocks can make you very wealthy.

Other stocks mentioned: EDIT, RHHBY
1 year ago - The Motley Fool

BURNABY, British Columbia, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the underwriters of its previous...

1 year ago - GlobeNewsWire

These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.

Other stocks mentioned: AUPH, ZYME
1 year ago - The Motley Fool

Xenon Pharmaceuticals Is Poised For Significant Progress In 2020

1 year ago - Seeking Alpha

Top Ranked Momentum Stocks to Buy for February 4th

Other stocks mentioned: MLNX, RLI
1 year ago - Zacks Investment Research

BURNABY, British Columbia, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announc...

1 year ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for January 24th

Other stocks mentioned: ACMR, MS, SIG
1 year ago - Zacks Investment Research

Does Xenon Pharmaceuticals (XENE) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten publi...

1 year ago - GlobeNewsWire

BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten...

1 year ago - GlobeNewsWire

Xenon ’ s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials  Anticipated to be Underway in 2020

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Xenon Pharmaceuticals.

1 year ago - Zacks Investment Research

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Xenon Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

About XENE

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a select... [Read more...]

Industry
Biotechnology
IPO Date
Nov 5, 2014
CEO
Simon Pimstone
Employees
123
Stock Exchange
NASDAQ
Ticker Symbol
XENE
Full Company Profile

Financial Performance

In 2020, XENE's revenue was $32.17 million, an increase of 371.02% compared to the previous year's $6.83 million. Losses were -$28.84 million, -30.67% less than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price forecast is 26.88, which is an increase of 47.33% from the latest price.

Price Target
$26.88
(47.33% upside)
Analyst Consensus: Strong Buy